Precision Optics Corporation Inc reported QQ2 2025 revenue of $4.527 million, down 9.9% year over year but up 7.9% quarter over quarter as production backlogs intensified. The quarter produced a material shift toward higher production activity driven by two major programs: a single-use cystoscope imaging module for an AI-powered robotic platform and a defense/aerospace assembly program. These gains culminated in a 42% sequential production increase from Q1 to Q2, the largest in several years and the highest production revenue since fiscal 2023, signaling an inflection point as the company scales manufacturing capacity to meet backlogs.
Despite the revenue ramp, QQ2 2025 profitability remained negative: gross margin was 23.6% on gross profit of $1.07 million, and operating income came in at an operating loss of $0.91 million with EBITDA of approximately -$0.86 million. Management attributed lower quarterly gross margins to a shift of engineering resources toward finalizing the Unity imaging platform and a higher proportion of non-billable product development activity, plus ongoing back-half ramp in manufacturing headcount. SG&A was $1.66 million for the quarter, and R&D expense rose to $0.32 million for the period, contributing to the quarterly net loss of about $0.97 million or $0.15 per share (diluted).
Management highlighted Unity as the centerpiece of the strategic growth engine, designed to accelerate time-to-market, reduce development risk, and enable a scalable portfolio by reusing baseline design elements. Unity launched at Photonics West (January) and MD&M West (February) with strong customer interest, setting the stage for a step-up in product development revenue in Q3 and especially Q4 as customer projects move into production. Management guided to a Q3 revenue target of at least $5.0 million and a Q4 target of at least $6.0 million, with Adjusted EBITDA turning positive in Q4 as backlogs translate into higher, more efficient production output. The company also outlined capacity expansion plans, including clean-room space additions, multiple production lines, and a shift-based manufacturing boost, to accommodate a multi-year backlog and drive margin improvements as scale improves.
The QQ2 2025 results underscore a company in transition: a fragile near-term profitability profile amid a substantive scale-up thesis centered on Unity-driven endoscope platforms and two high-value programs. The risk-reward is tied to the speed and execution of capacity expansion, regulatory clearance timelines, and sustained demand from key customers. If run-rate production reaches the projected levels and Unity-based programs scale as expected, POCI could transition toward sustainable EBITDA positivity in late FY2025 and beyond, supported by a significantly enlarged backlog and a more predictable production footprint.